8-K: Day One Biopharma's OJEMDA Nears EU Approval, Boosts Outlook

Day One Biopharmaceuticals' OJEMDA received a positive opinion from the European Medicines Agency's CHMP for conditional marketing authorization in relapsed or refractory BRAF-altered pediatric low-grade glioma.

Summary

• OJEMDA (tovorafenib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending conditional marketing authorization for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG).
• Ipsen Pharma SAS holds exclusive license rights to commercialize OJEMDA outside of the United States, as per an agreement from July 2024.
• U.S. net product revenue for OJEMDA reached $155.4 million in 2025, a 172% increase from 2024, with 4,635 prescriptions.
• The company projects 2026 U.S. net product revenue for OJEMDA to be between $225 million and $250 million, representing over 50% growth from 2025.
• Three-year follow-up data from the FIREFLY-1 pivotal Phase 2 trial for OJEMDA reinforced its durability, showing a median duration of response of 19.4 months and a median time to next treatment of 42.6 months.
• 77% of patients in the post-treatment observation period were treatment-free for at least 12 months, with no new safety signals observed.
• The FIREFLY-2 pivotal Phase 3 trial for front-line pLGG is expected to complete enrollment in the first half of 2026, with topline data anticipated mid-2027, potentially leading to approval in 2028.
• The pipeline includes Emi-Le (emiltatug ledadotin), a B7-H4-targeted antibody-drug conjugate (ADC) for Adenoid Cystic Carcinoma (ACC), with Phase 1 data expected mid-2026.
• DAY301, a PTK7-targeted ADC, is also in development with Phase 1a data expected in the second half of 2026.
• Cash, cash equivalents, and short-term investments totaled $441.1 million as of December 31, 2025.
• The net loss for the full year ended December 31, 2025, was $107.3 million, compared to a net loss of $95.5 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by the significant European regulatory progress for OJEMDA, robust U.S. commercial performance, and promising pipeline advancements, all contributing to a clear growth trajectory.

Positives

• Positive opinion from the European Medicines Agency's CHMP for OJEMDA's conditional marketing authorization, opening a significant new market.
• Strong U.S. OJEMDA net product revenue growth of 172% to $155.4 million in 2025, demonstrating robust commercial execution.
• Guidance for 2026 U.S. net product revenue of $225-$250 million, indicating continued strong growth of over 50%.
• Durable clinical benefit of OJEMDA reinforced by 3-year FIREFLY-1 data, with a median duration of response of 19.4 months and a median time to next treatment of 42.6 months.
• High treatment-free interval, with 77% of patients treatment-free for at least 12 months following 24 months of therapy.
• No new safety signals observed in the 3-year update of FIREFLY-1, supporting a favorable safety profile.
• Advancement of the pipeline with Emi-Le (Phase 1 data mid-2026) and DAY301 (Phase 1a data 2H 2026), targeting additional high-unmet-need cancers.
• Solid balance sheet with $441.1 million in cash, cash equivalents, and short-term investments at year-end 2025.

Negatives

• Net loss increased to $107.3 million in 2025 from $95.5 million in 2024.

Risks

• Forward-looking statements are inherently subject to known and unknown risks and uncertainties, some of which cannot be predicted or quantified.
• Actual results may differ materially and adversely from those anticipated or implied by forward-looking statements due to various factors, including those described in the company's most recent Annual Report on Form 10-K.
• The company's future financial performance, including the sufficiency of cash, cash equivalents, and short-term investments to fund operations, is subject to risks.
• The timing and success of commercialization and marketing efforts, nonclinical and clinical development activities, and the potential benefits of acquisitions and collaborations are uncertain.
• Efficacy and safety profiles of products and product candidates, and the ability of OJEMDA to treat pLGG or related indications, are subject to risk.
• The impact of global business or macroeconomic conditions, including inflation, fluctuating interest rates, supply chain disruptions, labor shortages, government shutdowns, political/trade/regulatory developments, and global regional conflicts, could affect the business and operations.
• The ability to protect intellectual property is a risk factor.
• Estimates and statistical data relating to market size and growth, and projections of future performance, are necessarily subject to a high degree of uncertainty and risk.

Future Outlook

The company expects 2026 U.S. net product revenue for OJEMDA to be between $225 million and $250 million, representing over 50% growth from 2025. Key clinical milestones include completing FIREFLY-2 enrollment in 1H 2026 with topline data expected mid-2027, leading to potential approval in 2028. Phase 1 data for Emi-Le is anticipated mid-2026, and Phase 1a data for DAY301 is expected in 2H 2026, with a goal to expand OJEMDA globally through Ipsen.

Management Comments

• Day One is inspired by the urgent needs of children and creatively and intentionally develops new medicines for people of all ages with life-threatening diseases.
• Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible.
• We build long-term value by boldly advancing care for patients of all ages with high unmet needs.

Industry Context

StockSavvy.ai notes that the positive CHMP opinion for OJEMDA positions Day One Biopharmaceuticals for significant expansion into the European pediatric oncology market, a crucial step for a commercial-stage biopharmaceutical company. This development, coupled with strong U.S. revenue growth and a robust pipeline of targeted therapies like Emi-Le and DAY301, indicates a strategic focus on high-unmet-need areas, aligning with broader industry trends towards precision medicine in rare diseases. The company's progress in pLGG, a disease with limited approved therapies, highlights its potential to establish new standards of care, differentiating it from general oncology players.

Comparison to Industry Standards

• OJEMDA's median duration of response of 19.4 months and median time to next treatment of 42.6 months in relapsed/refractory pLGG are highly competitive, especially given the lack of standard of care and approved therapies in this setting prior to OJEMDA. This compares favorably to historical chemotherapy regimens which often yield shorter progression-free survival and higher rates of recurrence.
• The company's strategy to expand OJEMDA into first-line pLGG with the FIREFLY-2 trial mirrors successful strategies seen with other targeted therapies, such as BRAF inhibitors in melanoma (e.g., dabrafenib + trametinib by Novartis or vemurafenib by Genentech/Roche), where initial approval in later lines of therapy is followed by expansion into earlier treatment settings to maximize market opportunity and patient benefit.
• The acquisition of Emi-Le for Adenoid Cystic Carcinoma (ACC) positions Day One in another high-unmet-need area, similar to how companies like Blueprint Medicines (with Ayvakit for gastrointestinal stromal tumors) or Loxo Oncology (acquired by Eli Lilly, with Vitrakvi for TRK fusion cancers) have targeted rare cancers with specific genomic alterations, aiming for rapid regulatory pathways due to significant unmet needs.

Stakeholder Impact

• **Shareholders**: Potential for increased shareholder value due to expanded market access for OJEMDA in Europe, strong U.S. revenue growth, and a promising pipeline, which could lead to higher stock valuation.
• **Patients (Pediatric Low-Grade Glioma)**: Increased access to OJEMDA as a treatment option in Europe, offering a new therapy for a serious and life-threatening disease with high unmet needs. The durable clinical benefits observed in FIREFLY-1 data provide hope for improved outcomes.
• **Healthcare Providers**: New treatment option (OJEMDA) for pediatric low-grade glioma patients in Europe, supported by clinical data reinforcing its role in the treatment paradigm.
• **Ipsen Pharma SAS**: Strengthened partnership and potential for significant revenue generation from commercializing OJEMDA outside the U.S.

Next Steps

• Ipsen to pursue conditional marketing authorization for OJEMDA in Europe.
• Solidify OJEMDA as 2L standard of care in relapsed/refractory pLGG.
• Maximize persistency of OJEMDA to optimize patient outcomes.
• Complete FIREFLY-2 trial enrollment in 1H 2026.
• Deliver FIREFLY-2 topline data by mid-2027.
• Advance Emi-Le with Phase 1 clinical data by mid-2026 and progress to later-stage development.
• Report Phase 1 updates from DAY301 in 2H 2026 and inform next development steps.
• Expand OJEMDA globally through Ipsen.

Key Dates

Recommendation

The positive CHMP opinion for OJEMDA represents a significant de-risking event and opens up a substantial new market in Europe, complementing the already strong U.S. commercial performance. The robust 2026 revenue guidance, coupled with compelling 3-year clinical data reinforcing OJEMDA's durability and the advancement of a promising pipeline (Emi-Le, DAY301) targeting other high-unmet-need cancers, positions Day One Biopharmaceuticals for accelerated growth and long-term value creation. The company's strong cash position further supports its strategic initiatives. This combination of regulatory success, commercial traction, and pipeline progress makes it a strong buy for investors.

Keywords

Day One Biopharmaceuticals, OJEMDA, tovorafenib, pediatric low-grade glioma, pLGG, BRAF-altered, relapsed refractory, CHMP, EMA, Ipsen, biopharmaceutical, oncology, brain tumor, Emi-Le, Adenoid Cystic Carcinoma, ACC, DAY301, ADC, PTK7, clinical trial, FIREFLY-1, FIREFLY-2, financial results, corporate presentation, biotech